Jefferies Group LLC reiterated their hold rating on shares of TESARO, Inc. (NASDAQ:TSRO) in a research report released on Friday morning. Jefferies Group LLC currently has a $124.00 target price on the biopharmaceutical company’s stock.
A number of other analysts have also recently issued reports on the company. Credit Suisse Group set a $198.00 price objective on TESARO and gave the company a buy rating in a research report on Wednesday, July 19th. ValuEngine lowered TESARO from a hold rating to a sell rating in a report on Monday, July 17th. Cann restated a buy rating and set a $199.00 target price on shares of TESARO in a report on Friday, September 8th. Gabelli initiated coverage on TESARO in a report on Friday, July 7th. They set a buy rating and a $175.00 target price on the stock. Finally, BidaskClub lowered TESARO from a sell rating to a strong sell rating in a report on Wednesday, July 19th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $166.10.
Shares of TESARO (NASDAQ TSRO) opened at $110.91 on Friday. TESARO has a 12-month low of $106.64 and a 12-month high of $192.94. The company has a quick ratio of 5.41, a current ratio of 5.69 and a debt-to-equity ratio of 0.34.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/11/06/tesaro-inc-tsro-earns-hold-rating-from-jefferies-group-llc.html.
In other TESARO news, VP Edward C. English sold 10,862 shares of TESARO stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the sale, the vice president now directly owns 6,258 shares of the company’s stock, valued at $844,329.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. Insiders have sold 35,692 shares of company stock worth $4,628,976 over the last ninety days. Company insiders own 34.60% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Exane Derivatives acquired a new stake in TESARO during the third quarter valued at approximately $106,000. Botty Investors LLC acquired a new stake in TESARO during the second quarter valued at approximately $140,000. Nordea Investment Management AB acquired a new stake in TESARO during the second quarter valued at approximately $167,000. Oppenheimer Asset Management Inc. boosted its holdings in TESARO by 3,042.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock valued at $206,000 after purchasing an additional 1,430 shares in the last quarter. Finally, BB&T Securities LLC acquired a new stake in TESARO during the second quarter valued at approximately $222,000.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
What are top analysts saying about TESARO Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO Inc. and related companies.